MIDAZOLAM (Versed)

ACTION:  Hypnotic, Sedative, Anti-Seizure
•  Midazolam is a potent, short-acting benzodiazepine with hypnotic and amnestic effects. It has no

effect on pain.

INDICATIONS:
•  Premedication before cardioversion, external pacing and other painful procedures.
•  Seizures (status epilepticus).
•  Agitated patient who may be a danger to self or others.

CONTRAINDICATIONS:
•  Hypersensitivity
•  Narrow-angle glaucoma

 POTENTIAL SIDE EFFECTS:

•  Laryngospasm
•  Bronchospasm
•  Dyspnea
•  Respiratory depression and arrest
•  Drowsiness
•  Amnesia

•  Shock, with depressed vital signs,

unless being used for cardioversion

•  Alcoholic coma

•  AMS
•  Bradycardia
•  Tachycardia
•  PVC’s
•  Nausea
•  Vomiting

ADULT DOSE/ROUTE:
  Sedation/Agitation:  5mg IM x1 or 5 mg slow push IV/IO.  Maximum total dose 5mg IV/IO
  Seizure: 10 mg IM x1 or intranasally (5mg each nostril) or 10mg slow push IV/IO. Maximum total

dose 10mg IV/IO

PEDIATRIC DOSE/ROUTE:
  Sedation/Agitation: 0.1 mg/kg IM (Max 5mg) x1 or 0.05 mg/kg (Max 5mg) slow push IV/IO.  May
repeat IV/IO dose in 5 minutes for continued agitation. Maximum total dose is 5 mg IV/IO.
  Seizure: 0.2 mg/kg IM x1 (Max 10mg) or intranasally (half in each nostril) or 0.2 mg/kg slow push
IV/IO (Max 10 mg) May repeat IV/IO dose in 5 minutes x1. Maximum total dose is 10 mg IV/IO

NOTES:
•  Contact Base Hospital if seizure activity continues after maximum dose is reached and additional

doses are required.

•  Contact Base Hospital if additional doses are needed for patients with continued agitation.
•  Do not use intranasal route in agitation because amount of absorption in an actively resisting,

agitated patients is unknown.

•  Effects of midazolam may be potentiated if administered with opiate pain medications. Contact

Base Hospital if considering administering both medications.

•  Always be prepared to protect airway and ventilate patients who are given benzodiazepines.

Continuous monitoring of vital signs before and after administration is required.

Effective: 04/01/25
Supersedes: 04/01/23

